Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extremely active murine amyloid enhancing factor

S Shtrasburg1, A Livneh, R Gal

  • 1Heller Institute of Medical Research, Sheba Medical Center, Tel Hashomer, Israel.

Clinical and Experimental Rheumatology
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Honeycomb appearance of fetal myofibromatosis.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2018
Same author

Immunoglobulin free light chains in saliva: a potential marker for disease activity in multiple sclerosis.

Clinical and experimental immunology·2017
Same author

T helper 17 polarization in familial Mediterranean fever.

Genes and immunity·2013
Same author

Pharmacokinetics of colchicine in pediatric and adult patients with familial Mediterranean fever.

International journal of immunopathology and pharmacology·2013
Same author

Exertional muscle pain in familial Mediterranean fever patients evaluated by MRI and 31P magnetic resonance spectroscopy.

Clinical radiology·2012
Same author

Exertional leg pain as a manifestation of occult spondyloarthropathy in familial Mediterranean fever: an MRI evaluation.

Scandinavian journal of rheumatology·2012
Same journal

The expanded cardiovascular risk prediction score as a cardiovascular mortality predictor in rheumatoid arthritis.

Clinical and experimental rheumatology·2026
Same journal

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Clinical and experimental rheumatology·2026
Same journal

Clinical features and gastrointestinal bleeding risk factors in IgA vasculitis patients: a retrospective study in a large volume centre.

Clinical and experimental rheumatology·2026
Same journal

Reply to the comment on: The microbiota in axial spondyloarthritis: what have we learned from Mendelian randomisation studies?

Clinical and experimental rheumatology·2026
Same journal

Comprehensive evaluation of bone structural and microarchitectural changes in rheumatoid arthritis treated with baricitinib using HR-pQCT, imaging, and biomarker analyses.

Clinical and experimental rheumatology·2026
Same journal

Tracking interstitial lung disease in systemic sclerosis: integrating lung magnetic resonance imaging into a clinically oriented multimodal follow-up strategy.

Clinical and experimental rheumatology·2026
See all related articles

Researchers generated a highly active amyloid enhancing factor (AEF) from mouse spleens. This potent AEF, with low molecular weight components, can induce amyloidosis rapidly in mice.

Area of Science:

  • Biochemistry
  • Immunology
  • Pathology

Background:

  • Amyloidosis is a group of diseases characterized by the deposition of amyloid proteins in various organs.
  • Amyloid enhancing factor (AEF) plays a crucial role in the development of amyloidosis.

Purpose of the Study:

  • To generate and characterize a novel, highly active amyloid enhancing factor (AEF).

Main Methods:

  • AEF was isolated from homogenized spleens of amyloidotic and pre-amyloidotic mice using 50% acetone.
  • The activity of AEF was assessed based on generation procedures, dosage, induction duration, and solvent effects.
  • Polyacrylamide gel electrophoresis and dialysis were used for characterization.

Main Results:

  • Priming the splenic source with an amyloidogen and acetone processing were critical for AEF activity.

Related Experiment Videos

  • A single intravenous dose of 1 nanogram of AEF induced amyloidosis in mice within 2-6 days.
  • Electrophoresis revealed two protein bands (9-11 KD) unique to AEF, and dialysis confirmed active components with MW ≤ 12 KD.

    • Conclusions:

    • The generated AEF is highly potent, representing the most active form currently available.
    • The active constituents of this AEF are low molecular weight (< or = 12 KD) molecules.
    • These low molecular weight components appear in the spleen during the process of amyloidogenesis.